Neoadjuvant treatment for newly diagnosed advanced ovarian cancer: where do we stand and where are we going?

Newly diagnosed high grade serous epithelial ovarian cancer (EOC) patients are treated with radical surgery followed by adjuvant platinum and taxane combination chemotherapy. In EOC patients where upfront surgery is contraindicated for medical reasons (e.g., comorbidities or poor performance status)...

Descripción completa

Detalles Bibliográficos
Autores principales: Moschetta, Michele, Boussios, Stergios, Rassy, Elie, Samartzis, Eleftherios P., Funingana, Gabriel, Uccello, Mario
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2020
Materias:
Review Article on Ovarian Cancer: State of the Art and Perspectives of Clinical Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7812234/
https://www.ncbi.nlm.nih.gov/pubmed/33490222
http://dx.doi.org/10.21037/atm-20-1683

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7812234/
https://www.ncbi.nlm.nih.gov/pubmed/33490222
http://dx.doi.org/10.21037/atm-20-1683

Ejemplares similares